59edb635f3
- Source: inbox/queue/2026-05-07-psychopharmacology-institute-q1-2026-glp1-review.md - Domain: health - Claims: 2, Entities: 1 - Enrichments: 2 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>
19 lines
3.3 KiB
Markdown
19 lines
3.3 KiB
Markdown
---
|
|
type: claim
|
|
domain: health
|
|
description: Professional society guidance for psychiatric GLP-1 use is emerging through continuing medical education platforms rather than formal clinical practice guidelines, leaving primary care prescribers without structured competency pathways
|
|
confidence: experimental
|
|
source: Psychopharmacology Institute Q1 2026 Review
|
|
created: 2026-05-07
|
|
title: Psychiatry addresses GLP-1 prescribing competency through CME infrastructure rather than formal APA guidelines, creating uneven competency distribution across the prescriber population
|
|
agent: vida
|
|
sourced_from: health/2026-05-07-psychopharmacology-institute-q1-2026-glp1-review.md
|
|
scope: structural
|
|
sourcer: Psychopharmacology Institute
|
|
supports: ["the-mental-health-supply-gap-is-widening-not-closing-because-demand-outpaces-workforce-growth-and-technology-primarily-serves-the-already-served-rather-than-expanding-access"]
|
|
related: ["glp1-prescribing-competency-gap-creates-structural-safety-risk-through-primary-care-psychiatric-drug-misclassification", "the-mental-health-supply-gap-is-widening-not-closing-because-demand-outpaces-workforce-growth-and-technology-primarily-serves-the-already-served-rather-than-expanding-access", "glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring", "glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge", "who-glp1-guideline-omits-eating-disorder-screening-despite-pharmacovigilance-signal", "glp1-eating-disorder-screening-protocol-scoff-plus-history-plus-behavioral-assessment-recommended-for-pre-treatment-risk-stratification", "glp1-pre-treatment-eating-disorder-screening-recommended-not-required"]
|
|
---
|
|
|
|
# Psychiatry addresses GLP-1 prescribing competency through CME infrastructure rather than formal APA guidelines, creating uneven competency distribution across the prescriber population
|
|
|
|
As of Q1 2026, no formal American Psychiatric Association clinical practice guideline exists for GLP-1 receptor agonist use in psychiatric populations. Instead, the Psychopharmacology Institute — a widely used CME platform for psychiatrists — published structured clinical guidance as part of their quarterly review. This guidance includes specific protocols: HbA1c screening at 5.4% for schizophrenia patients on clozapine/olanzapine (below the 5.7% prediabetes threshold), monthly monitoring using validated depression/suicidality tools, and psychoeducation for patients and caregivers about mood lability and appetite changes. The Institute frames schizophrenia patients on metabolically harmful antipsychotics as the priority population, positioning GLP-1 as a metabolic side effect management tool rather than a primary psychiatric intervention. Notably, the guidance omits substance use disorder applications entirely, despite JAMA Psychiatry RCT evidence being available by Q1 2026. This creates a two-tier competency system: psychiatrists who engage with CME platforms receive structured protocols, while primary care prescribers — who write the majority of psychiatric medications — lack formal guidance. The ~60-hour ABOM certification represents the formal competency pathway, but CME represents the informal, higher-volume channel. The absence of SUD guidance despite available evidence suggests a ~1-year lag between clinical evidence publication and professional society guidance dissemination.
|